Investors bet on obesity drugs before without much success. Why this next wave could be different

Josephine Flood | CNBC

It's been nearly a decade since the American Medical Association declared obesity a disease, but treating it has been complicated and muddled by the lingering perception that the condition is more about lifestyle and appearance than biology.

New obesity therapies are drawing a clearer line between mechanisms in the body and the difficulty some have losing weight — demonstrating hurdles no amount of willpower can overcome. The treatments are making greater amounts of weight loss possible, offering patients hope and investors a potential opportunity.

More In Deep Dives

CNBC ProThe grand 'work from anywhere' experiment got a few things wrong. Here's how companies are fixing it.
CNBC ProLithium's vital role in the energy transition sends prices to record highs. How to play it
CNBC ProThe economic outlook may not be as bad as the market fears. Here's where investors should be looking